A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study

You may be eligible if

• Male or female, age greater than or equal to 18 years at the time of signing informed consent
• Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening
• Subjects fulfilling at least one of the below criteria:
• Experienced at least one severe hypoglycaemic episode within the last year prior to screening (according to the American Diabetes Association definition, January 2018)\*
• Moderate renal impairment defined as estimated glomerular filtration rate value of 30-59 mL/min/1.73 m\^2 as defined by Kidney Disease Improving Global Outcomes 2012 at screening
• Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8 at screening
• Treated with insulin for more than 5 years
• Episode of hypoglycaemia (defined a glucose alert value of 70 mg/dL (3.9 mmol/L) or less, i.e., Level 1) within the last 12 weeks prior to screening visit
• Treated with any basal insulin greater than or equal to 90 days prior to the day of screening with or without any of the following anti-diabetic drugs:
• Metformin
• Dipeptidyl peptidase-4 inhibitor
• Sodium-glucose co-transporter 2 inhibitor
• Alpha-glucosidase-inhibitors (acarbose)
• Thiazolidinediones
• Marketed oral combination products only including the products listed above
• HbA1c less than or equal to 9.5% (80 mmol/mol) at screening confirmed by central laboratory analysis
• Body mass index less than or equal to 45 kg/m\^2 \*Hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery
• Anticipated initiation or change in concomitant medications known to affect weight or glucose metabolism (e.g., treatment with orlistat, thyroid hormones, or corticosteroids)
• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or another suitably qualified health care provider within the past 90 days prior to screening or in the period between screening and run-in